Investors

Two approvals in 2024 established that the NPC1 market is real and that it pays. Neither addresses the lipid accumulation driving the disease.

Commercial opportunity

The market for NPC treatments was historically restricted to off-label therapies and symptomatic care. According to market research from DataM Intelligence and Decisions Advisors, the global NPC treatment market is projected to grow at a compound annual growth rate of between 14% and 28%, expanding from its 2024 baseline to exceed $1.2 billion by the 2033 to 2035 period.

Pricing for ultra-rare lysosomal storage disease therapies commands a significant premium. The FDA approvals of the first two NPC-specific therapies in September 2024 validated commercial viability and established the pricing paradigm in this space.

>$1.2B

Projected global NPC treatment market by 2033–2035, at a 14–28% CAGR from a 2024 baseline (DataM Intelligence; Decisions Advisors)

$500–600K

Estimated average annual cost per patient of Miplyffa (arimoclomol), on a wholesale acquisition cost of approximately $40,000–$106,000 per month depending on dosage (Reuters)

~$300K

Estimated annual wholesale acquisition cost of Aqneursa (levacetylleucine) based on recommended dosing (Oklahoma Health Care Authority)

7 years

Orphan Drug Exclusivity on approval, if Orphan Drug Designation is granted. We intend to seek designation; it may not be granted.

Third-party market projections are estimates and may prove inaccurate. Pricing figures describe therapies marketed by other companies and are not indicative of any price Myra EB Bio may achieve. UNDC-005 is not approved for any use.

A second, larger market with no approved option

The adoption of GLP-1 receptor agonists for obesity has created a clinical gap at discontinuation. Retrospective claims analyses indicate that up to 70% of patients prescribed GLP-1 therapies discontinue within 12 months, and published clinical data show that patients typically regain 50% to 80% of lost weight within six to twelve months of stopping. There are currently no approved pharmacologic therapies designed to prevent this rebound.

UNDC-005 is not a GLP-1 agonist and is not designed to compete with existing GLP-1 therapies. It is being developed as a complementary oral off-ramp. This program runs on a track independent of NPC1 and has not entered clinical development.

~30M

Projected US GLP-1 users by 2030

Up to 70%

Of patients prescribed GLP-1 therapies discontinue within 12 months, per retrospective claims analyses

50–80%

Of lost weight typically regained within six to twelve months of discontinuation

None

Approved pharmacologic therapies specifically designed to prevent post-GLP-1 metabolic rebound

SEC filings

Our filings

Myra EB Systems Inc. has filed a registration statement on Form S-1 with the Securities and Exchange Commission in connection with a direct listing. Once effective, all of our filings will be available free of charge through the SEC's EDGAR database.

Form S-1 Registration Statement under the Securities Act of 1933 On file with the SEC

Search EDGAR →

This website does not constitute an offer to sell or a solicitation of an offer to buy any securities, and there will be no sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. Any offering is made only by means of a prospectus forming part of the registration statement. Information on this website is not incorporated by reference into any filing.

Corporate presentation

A downloadable corporate presentation will be posted here. In the meantime, the registration statement on file with the SEC is the authoritative description of our business, our programs, and the risks associated with them.

Investor enquiries

Myra EB Systems Inc., 85 Swanson Road, Suite 293, Boxborough, MA 01719. Telephone (401) 225-2107.

Contact investor relations